CROHN'S DISEASE

This phase 3 trial tests duvakitug, an injected drug, in about 980 adults with moderate to severe Crohn's disease who haven't improved with other treatments. The study is double-blind and placebo-controlled, meaning some participants get the drug and some get a dummy shot. The go…

This study tests whether increasing the dose of guselkumab can help people with Crohn's disease who don't get better with standard doses. About 210 adults with active Crohn's will receive guselkumab, and after 12 weeks, those who haven't responded will get a higher dose more ofte…

This phase 3 trial is testing a drug called tulisokibart in about 1,200 people with moderate-to-severe Crohn's disease who haven't had success with other treatments. The drug is given by IV or injection and aims to reduce symptoms and heal the gut lining. The study compares tulis…

This study is testing the drug vedolizumab (Entyvio) in 400 adults with moderate to severe ulcerative colitis or Crohn's disease. Participants first receive the drug through an IV for 6 weeks, then switch to injections under the skin for the rest of the year. The main goal is to …

This phase 2 trial is testing four different drugs—risankizumab, trosunilimab, lutikizumab, and ABBV-8736—in about 540 adults with moderate to severe Crohn's disease. The goal is to see if these targeted therapies can reduce inflammation and improve symptoms. Participants will re…

This study follows 40 children with Crohn's disease or ulcerative colitis who developed severe psoriasis from anti-TNF drugs and switched to ustekinumab. Researchers will check if their digestive symptoms stay controlled and if their skin improves after 3-6 months. The goal is to…

This study tests upadacitinib (RINVOQ), a daily oral medication, in 110 children aged 2 to 18 with moderate to severe Crohn's disease who haven't improved with other treatments. The trial has three parts: an initial 12-week open-label phase, a 52-week double-blind maintenance pha…

This study tests the long-term safety and effectiveness of mirikizumab in 150 children and adolescents with moderate-to-severe ulcerative colitis or Crohn's disease. Participants who completed earlier mirikizumab studies can join. The trial lasts about 172 weeks and aims to see i…

This study tracks 250 people with moderate-to-severe Crohn's disease who are switching to either upadacitinib or risankizumab after a first treatment didn't work well enough. Researchers will see if these drugs help patients achieve remission without needing steroids over 18 mont…

This study tests whether adding the weight-loss drug tirzepatide to the Crohn's drug mirikizumab helps people with moderate-to-severe Crohn's disease who are also overweight or have obesity. About 290 adults will receive either mirikizumab alone or mirikizumab plus tirzepatide. T…

This study tests an experimental pill called MORF-057 (zotemtegrast) in 385 adults with moderate-to-severe Crohn's disease. The drug works by blocking a protein that drives gut inflammation. Participants will receive one of three doses of the drug or a placebo for 14 weeks to see…

This phase 3 study tests whether duvakitug can help people with moderate-to-severe Crohn's disease maintain remission. About 751 participants who responded to prior treatment will receive either duvakitug or a placebo injection for up to 40 weeks, with an option to continue in an…

This study looks at the long-term safety of a drug called vedolizumab given as a shot under the skin to children and teenagers with ulcerative colitis or Crohn's disease. About 70 participants who did well on the drug in an earlier study will keep getting it, while those who didn…

This study tests an experimental drug called SAR441566 in 260 adults with moderate to severe Crohn's disease. Participants will receive different doses of the drug or a placebo for up to 52 weeks to see if it reduces gut inflammation and improves symptoms. The goal is to find a s…

This study will follow 500 people with Crohn's disease or ulcerative colitis who are starting guselkumab, a biologic drug. Researchers will measure how many achieve remission and how the treatment affects daily life, including fatigue and work productivity. The goal is to underst…

This study tracks 220 adults with moderate-to-severe ulcerative colitis or Crohn's disease who are starting guselkumab, a biologic drug. Researchers will measure how many achieve remission (symptom control) and whether they can stop steroids. The goal is to see how well the drug …

This study tests a drug called guselkumab in 120 children with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut lining over 52 weeks. Participants must have active Crohn's confirmed by endoscopy. This is a phase 3 trial, meaning it…

This study tests risankizumab, a drug already used in adults, in children aged 2 to 18 with moderate to severe Crohn's disease. About 110 kids will receive the drug intravenously then by injection over several years. The goal is to see if it safely reduces symptoms and gut inflam…

This study tests whether giving two drugs together (vedolizumab and upadacitinib) for 12 weeks works better than vedolizumab alone to reduce bowel inflammation and ulcers in adults with moderate to severe Crohn's disease. About 396 participants will receive the combo or a placebo…

This phase 3 trial tests mirikizumab, an injected drug, in 90 children with moderate-to-severe Crohn's disease. The study looks at whether the drug can improve symptoms and heal the gut lining over 52 weeks. Participants receive mirikizumab during a 12-week induction period, then…

This study tests the long-term safety of an oral drug called zasocitinib (TAK-279) in adults with moderate to severe Crohn's disease or ulcerative colitis. Participants who responded to the drug in earlier studies can continue treatment for up to 3 years. The main goal is to see …

This study tests if the drug vorinostat is safe and can help people with moderate-to-severe Crohn's disease by reducing gut inflammation. Participants who respond well may then receive a maintenance treatment with ustekinumab for up to two years. The goal is to control symptoms a…

This study looks at whether a special liquid diet called exclusive enteral nutrition (EEN) can help adults with active Crohn's disease feel better and reduce inflammation. About 300 participants will use EEN as their main treatment for 12 weeks. Researchers will check remission r…

This study tests whether a newer surgical method called Kono-S anastomosis can better prevent Crohn's disease from returning after bowel surgery compared to the standard side-to-side technique. About 600 adults with Crohn's disease needing bowel resection will be randomly assigne…

This study looks at how children and teenagers with moderate to severe ulcerative colitis or Crohn's disease process a drug called vedolizumab when given as a shot under the skin. About 70 participants who already responded to vedolizumab given through a vein will receive the sho…

This study tests an oral drug called TAK-279 (Zasocitinib) in 268 adults with moderate-to-severe Crohn's disease who haven't responded well to other treatments. Participants take one of three doses or a placebo daily for 12 weeks to see if it reduces gut inflammation and ulcers, …

This study is for children with ulcerative colitis or Crohn's disease who already completed a previous vedolizumab trial. It aims to see how safe the drug is over a longer period. About 240 kids will receive vedolizumab infusions or be observed without treatment. Researchers will…

This study looks at 220 adults with Crohn's disease whose symptoms returned while on adalimumab. Half will get a higher dose of adalimumab, and the other half will switch to vedolizumab. The goal is to see which approach leads to better control of the disease after 24 weeks, usin…

This study watches how well IL-23 inhibitors work for adults with active Crohn's disease in everyday clinics. About 665 people will get treatment chosen by their doctor and be checked at 12 and 52 weeks. The main goal is to see how many reach remission (symptom-free) by week 12, …

This study tests whether adding a special diet (Crohn's Disease Exclusion Diet) to standard medication helps children with unstable Crohn's disease have fewer flare-ups over a year. About 120 kids aged 6-17 will be randomly assigned to either diet plus medication or medication al…

This phase 2 trial is testing an experimental drug called SAR442970 in about 99 adults with moderate to severe Crohn's disease. Participants will receive either the drug or a placebo as a shot under the skin. The main goal is to see if the drug can improve the appearance of the g…

This study is testing whether combining two different biologic drugs can better control moderate to severe Crohn's disease. One hundred adults will first receive either vedolizumab plus adalimumab or vedolizumab plus ustekinumab. Those who respond well will then switch to vedoliz…

This Phase 2 study is testing two new drugs, MT-501 and MT-201, in 140 adults with moderate-to-severe Crohn's disease or ulcerative colitis. The goal is to see if these treatments are safe and can improve symptoms and gut healing. Researchers will monitor side effects and measure…

This program provides children and teenagers with moderate to severe ulcerative colitis or Crohn's disease continued access to vedolizumab, a medication given through a vein, after they finish a related study. It is for those who still benefit from the treatment and have no good …

This study follows about 240 people in Japan with moderate to severe Crohn's disease who are taking upadacitinib, an approved drug. Researchers will track side effects and how well the drug controls the disease over up to 64 weeks. The goal is to see how the drug works in everyda…

This study tests whether high-dose chemotherapy followed by a stem cell transplant can help people with severe Crohn's disease that hasn't responded to other treatments. It includes up to 20 children and adults aged 10 to 60. The goal is to see if the approach is safe and can red…

This study tests whether adding a structured coping skills program to standard biologic medication improves emotional well-being and disease remission in people with early Crohn's disease. 170 adults with active Crohn's for less than 5 years will receive either the coping program…

This study follows 275 Crohn's disease patients in Japan who receive darvadstrocel, a stem cell injection, for complex anal fistulas. Researchers will monitor side effects and whether fistulas close over 36 months. The goal is to see if this treatment is safe and works in real-wo…

This phase 3 trial tests the drug vedolizumab in 408 adults in China with moderate-to-severe Crohn's disease. Participants receive IV infusions of vedolizumab or a placebo over several weeks. The goal is to see if vedolizumab can reduce symptoms like abdominal pain and diarrhea, …

This study is testing whether adding the antifungal drug fluconazole to standard IL-23 therapy helps people with mild to moderate Crohn's disease. About 120 adults will be randomly assigned to receive either fluconazole or a placebo alongside their usual treatment. The main goal …

This study is testing a new stool test that measures calprotectin, a protein that signals inflammation in the gut. The goal is to see if the test can help doctors diagnose Crohn's disease or ulcerative colitis and tell them apart from irritable bowel syndrome. About 220 adults wi…

This early-phase study tests whether a special PET scan tracer, Ga68-FAPI-46, can detect early fibrosis (scarring) in the small bowel of people with Crohn's disease. About 45 participants will be divided into those with known strictures and those without, to compare scan results.…

This study is testing whether a shorter, abbreviated MRI scan (called MRE) works just as well as the standard, longer scan for detecting inflammation and damage in the bowel of people with Crohn's disease. Researchers will enroll 300 children and adults who already need an MRE as…

This study tests whether combining repetitive transcranial magnetic stimulation (rTMS) with an anti-inflammatory diet can reduce constipation and improve quality of life in people with Crohn's disease. Fifty patients aged 40-60 will be split into two groups: one gets both rTMS an…

This study tests whether using virtual reality (VR) can safely reduce abdominal pain in people with Crohn's disease who are not currently experiencing active inflammation. Researchers at Mayo Clinic will enroll 15 participants to see if VR improves pain and quality of life over 1…

This study looks at whether a 12-week remote exercise program can improve quality of life for people with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. About 72 adults with IBD will use a smartphone app to follow guided physical activities at…

This study is tracking over 25,000 people with inflammatory bowel disease (IBD) to understand why many continue to have abdominal pain even when their disease is in remission. Researchers will use questionnaires, blood and stool samples, heart rate recordings, and genetic data to…

This study is looking at whether a substance in the blood called LRG can help doctors tell how active ulcerative colitis or Crohn's disease is in the gut. Researchers will measure LRG levels in 300 people who might have these conditions and compare them with what is seen during a…

This study observes how doctors use a treat-to-target strategy for people with Crohn's disease or ulcerative colitis in routine care. Researchers will review medical records of 2000 adults over 24 months to see if adjusting treatment based on disease activity improves outcomes. N…

This study follows 300 adults with Crohn's disease who are starting standard treatments like vedolizumab or IL-23 blockers. Researchers will track how quickly patients feel improvements in pain, fatigue, and daily functioning using simple questionnaires. The goal is to better und…

This study follows 945 women with Crohn's disease or ulcerative colitis to see how pregnancy affects their condition. Researchers will track disease flares during pregnancy, after childbirth, and during breastfeeding. The goal is to better understand the link between IBD and preg…

This study surveys 400 adults with inflammatory bowel disease (IBD) from two medical centers to understand how social factors like insurance, income, and support affect medication adherence and quality of life. Researchers focus on Hispanic and Black patients, who often have wors…

This research study collects health information from 10,000 people with brain inflammation conditions like Long COVID, ME/CFS, and autoimmune diseases. Participants use a smartphone app to share symptoms, health history, and wearable data. The goal is to find disease subtypes and…

This study is for adults in South Korea with ulcerative colitis or Crohn's disease who are already taking vedolizumab injections. Researchers will look at medical records to track side effects and how well the treatment works. No new medicine or treatment is given—this is just an…

This study aims to understand why Crohn's disease often returns after surgery by examining specific immune cells that respond to a protein called IL-23. Researchers will collect tissue samples from 40 patients with Crohn's disease during routine colonoscopies, before and after 12…

This study follows 48 adults with active Crohn's disease or ulcerative colitis who are starting biologic or JAK inhibitor therapy. Researchers use a quick, painless bioelectrical impedance scan to measure muscle mass and other body composition changes at the start, 24 weeks, and …